Adverse events in patients treated with deutetrabenazine were more common during titration than maintenance, a finding that provides “important context for the dosing schedule to providers and patients.”
A decrease of 3 points on the Abnormal Involuntary Movement Scale score is the minimal clinically important difference for treatment of tardive dyskinesia with deutetrabenazine, according to a poster presented at Psych Congress 2020.
Despite the impact the COVID-19 pandemic has had on psychiatry practice, a proactive, routine, and systematic assessment for tardive dyskinesia in patients taking antipsychotics is a mandate for all clinicians, Rakesh Jain, MD, MPH, said at Psych…
Mary, a 22-year old woman with bipolar disorder, is taking an antipsychotic medication and has been exhibiting mild to moderate TD symptoms. Today, she is interviewing for a job at a local branch office of an insurance agency, and is worried how her potential employer will react to her facial grimacing and rapid eye blinking. Based on results of a recent large survey, TD symptoms may impact the employer’s perceptions most negatively in terms of whether or not Mary: